ArticleFrontiers in neurology2025
Safety and efficacy of short-term tirofiban combined with dual antiplatelet therapy after flow diverter placement for intracranial aneurysms: a multicenter retrospective study and nomogram for thromboembolic event prediction.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Flow diverters (FDs) are increasingly applied for intracranial aneurysms, but their high metal coverage raises thromboembolic risk. Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is standard, yet clopidogrel resistance, especially in Asian populations, reduces efficacy. Tirofiban, a glycoprotein IIb/IIIa inhibitor, may enhance perioperative protection. This study evaluated the safety and efficacy of adding short-term tirofiban to DAPT after FDs treatment and developed a model to predict thromboembolic events (TEEs). Methods: We retrospectively analyzed 319 patients with unruptured aneurysms treated with FDs across multiple centers (2018-2022). Patients received either DAPT alone (group 1) or DAPT plus tirofiban (group 2). After propensity score matching (140 per group), ischemic and hemorrhagic complications were compared. Predictive factors for TEEs were identified using Lasso-logistic regression, and a nomogram was constructed. Results: A total of 389 aneurysms in 319 patients were included in the statistical analysis. There were no statistically significant differences in the baseline characteristics of the patients and aneurysms between the groups, indicating comparability. After PSM, 140 patients were included in each group for comparison. The group 1 vs. the group 2 (Early postoperative complications): TEEs (3.6% vs. 5.0%, Conclusion: Tirofiban combined with DAPT in flow diverter treatment for intracranial aneurysms demonstrated good safety without increasing bleeding risk, though its efficacy advantage over DAPT alone was not evident. The proposed nomogram enables individualized TEE risk prediction and supports personalized antiplatelet management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.